Payback Time For Lilly? Erbitux Follow-on Succeeds In Squamous Lung Cancer Trial
This article was originally published in The Pink Sheet Daily
Lilly’s necitumumab – gained through the company’s ImClone acquisition – demonstrates an overall survival benefit in the SQUIRE study against first-line metastatic squamous NSCLC. Pleasantly surprised by the outcome, some analysts start to expect blockbuster sales.